Literature DB >> 22319033

Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.

Laure Cazabat1, Jérôme Bouligand, Sylvie Salenave, Michèle Bernier, Stephan Gaillard, Fabrice Parker, Jacques Young, Anne Guiochon-Mantel, Philippe Chanson.   

Abstract

CONTEXT: Germline mutations of the AIP (aryl-hydrocarbon receptor interacting protein) gene are associated with a predisposition to pituitary adenomas. Such mutations are found in about half of patients with familial acromegaly, but penetrance is incomplete.
OBJECTIVE: We studied the prevalence of germline AIP mutations in a large cohort of patients with apparently sporadic pituitary adenomas. PATIENTS AND
SETTING: A total of 443 patients with pituitary adenomas of all histotypes, who had no familial history of pituitary adenomas or multiple endocrine neoplasia and who were examined at Bicêtre University Hospital, a tertiary referral center, between 2007 and 2010, were enrolled in this prospective study.
METHODS: The entire coding sequence of the AIP gene was screened for germline mutations. A subgroup of patients were screened for large deletions or duplications of the AIP and MEN1 genes by multiplex ligation-dependent probe amplification.
RESULTS: AIP mutations were detected in 16 (3.6%) of the 443 patients, comprising six of 148 patients with acromegaly (4.1%), six of 132 patients with prolactinomas (4.5%), one of 113 patients with nonfunctioning adenomas (0.9%), three of 44 patients with corticotropic adenomas (6.8%), and none of the six patients with thyrotropic adenomas. This is the first report of an AIP mutation leading to a truncated protein in a patient with Cushing's disease. Patients with AIP mutation were younger at diagnosis (24.1 vs. 42.8 yr) and had predominantly macroadenoma (12 of 16). No mutations were found in patients diagnosed after age 40 yr, whereas the prevalence before this age was 7.2% (16 of 222). Studies of seven of the AIP-mutated patients' families showed that one asymptomatic parent carried the same mutation in each case.
CONCLUSION: This large prospective cohort study confirms the very low prevalence of germline AIP mutations in patients with apparently sporadic pituitary adenomas. We propose to limit AIP testing to patients diagnosed before age 40 yr with apparently sporadic large pituitary adenomas, especially GH- or PRL-secreting adenomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22319033     DOI: 10.1210/jc.2011-2291

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

1.  Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas?

Authors:  Sema Yarman; Yeliz Duvarci Ogret; Fatma Savran Oguz
Journal:  Genet Test Mol Biomarkers       Date:  2015-05-04

Review 2.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

3.  The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.

Authors:  Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke
Journal:  J Clin Endocrinol Metab       Date:  2015-05-05       Impact factor: 5.958

4.  Pituitary gland: New pathways in the pathogenesis of pituitary adenomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Nat Rev Endocrinol       Date:  2012-08-07       Impact factor: 43.330

Review 5.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

Review 6.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

Review 7.  The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.

Authors:  Catrin Lloyd; Ashley Grossman
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

9.  Should aip gene screening be recommended in family members of FIPA patients with R16H variant?

Authors:  Maria Chiara Zatelli; Maria Luisa Torre; Rachele Rossi; Marta Ragonese; Francesco Trimarchi; Ettore degli Uberti; Salvatore Cannavò
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

10.  Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Muge Sayitoglu; Fatma Ela Keskin; Sinem Firtina; Khusan Khodzhaev; Tugce Apaydin; Nurperi Gazioglu; Necmettin Tanriover; Buge Oz; Pinar Kadioglu
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.